Cargando…
Impact of pre‐therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV‐specific T‐cell therapy
OBJECTIVES: Clinical response to antibody‐based immunotherapies targeting checkpoint inhibitors is critically dependent on the tumor immune microenvironment (TIME). However, the precise impact of the TIME on adoptive cellular immunotherapy remains unexplored. Here we have conducted a long‐term follo...
Autores principales: | Walker, David G, Shakya, Reshma, Morrison, Beth, Neller, Michelle A, Matthews, Katherine K, Nicholls, John, Smith, Corey, Khanna, Rajiv |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946915/ https://www.ncbi.nlm.nih.gov/pubmed/31929892 http://dx.doi.org/10.1002/cti2.1088 |
Ejemplares similares
-
Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme
por: Jan, Chia-Ing, et al.
Publicado: (2018) -
Cytomegalovirus as a Novel Target for Immunotherapy of Glioblastoma Multiforme
por: Schuessler, Andrea, et al.
Publicado: (2014) -
Glioblastoma Multiforme Therapy and Mechanisms of Resistance
por: Ramirez, Yulian P., et al.
Publicado: (2013) -
Emerging Cellular Therapies for Glioblastoma Multiforme
por: Choi, Paul J, et al.
Publicado: (2018) -
Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment
por: Jackson, Christopher, et al.
Publicado: (2011)